Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13284444 | 0.98 | HTT (0.46) | POLBTSHRKMT2AHTTKDM4E | |
| SCHEMBL23089860 | 0.82 | HTT (0.43) | TSHRHTTLMNATP53 | |
| SCHEMBL4102300 | 0.81 | HTT (0.42) | TSHRHTTLMNATP53 | |
| SCHEMBL3581192 | 0.81 | CA12 (0.52) | POLBTSHRKMT2AHTTKDM4E | |
| SCHEMBL24981480 | 0.81 | HTT (0.39) | POLBTSHRHTTLMNATP53 | |
| SCHEMBL18424881 | 0.80 | HTT (0.41) | TSHRHTTLMNATP53 | |
| SCHEMBL4111848 | 0.79 | HTT (0.40) | TSHRHTTLMNATP53MAPK1 | |
| SCHEMBL3432500 | 0.79 | HTT (0.40) | TSHRHTTLMNATP53 | |
| SCHEMBL1157477 | 0.79 | HTT (0.58) | TSHRKMT2AHTTKDM4EALDH1A1 | |
| SCHEMBL6300741 | 0.79 | HTT (0.58) | TSHRKMT2AHTTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210040062-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2021-02-11 | — | — | US | disclosed |
| EP-3418276-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | Taisho Pharmaceutical Co., Ltd. (JP) | 2018-12-26 | — | — | EP | disclosed |
| EP-2661436-B1 | NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2016-04-13 | — | — | EP | disclosed |
| EP-2661436-B1 | NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2016-04-13 | — | — | EP | disclosed |
| US-9233964-B2 | Sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use therof | LEO PHARMA A/S (DK) | 2016-01-12 | — | — | US | disclosed |
| US-9233964-B2 | Sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use therof | LEO PHARMA A/S (DK) | 2016-01-12 | — | — | US | disclosed |
| US-9233964-B2 | Sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use therof | LEO PHARMA A/S (DK) | 2016-01-12 | — | — | US | disclosed |
| US-9233947-B2 | Sulfamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2016-01-12 | — | — | US | disclosed |
| US-9233947-B2 | Sulfamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2016-01-12 | — | — | US | disclosed |
| US-9233947-B2 | Sulfamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2016-01-12 | — | — | US | disclosed |
| US-20130237547-A1 | SULFAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-09-12 | — | — | US | disclosed |
| US-20130237547-A1 | SULFAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-09-12 | — | — | US | disclosed |
| US-8436041-B2 | Sulfamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-05-07 | — | — | US | disclosed |
| US-8436041-B2 | Sulfamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-05-07 | — | — | US | disclosed |
| US-8436041-B2 | Sulfamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-05-07 | — | — | US | disclosed |
| WO-2010080397-A1 | SULFAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-15 | — | — | WO | disclosed |
| US-20100160337-A1 | SULFAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2010-06-24 | — | — | US | disclosed |
| US-20100160337-A1 | SULFAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2010-06-24 | — | — | US | disclosed |
| US-20100160337-A1 | SULFAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2010-06-24 | — | — | US | disclosed |
| EP-2189454-A1 | Novel salts of 6-heterocyclyl substituted hexahydrophenanthridine derivatives | Nycomed GmbH (DE) | 2010-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237547-A1 | SULFAMIDES AS TRPM8 MODULATORS | TRPM8, TRPM5, TRPM2 | POLB 4606/4885TSHR 626/4885KMT2A 1053/4885 |
| US-20100160337-A1 | SULFAMIDES AS TRPM8 MODULATORS | TRPM8, TRPM5, TRPM2 | POLB 4606/4885TSHR 626/4885KMT2A 1053/4885 |
| US-20210040062-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | CYP2F1, CYP21A2, CYP11B1 | POLB 4110/4885TSHR 2861/4885KMT2A 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.